Gilead Sciences, Inc. (GILD) is scheduled to report its fourth-quarter and full-year results on February 6. Wall Street expects the biotech major to post lower revenue on a year-over-year basis, while its EPS is expected to increase. In this piece, I have discussed why it could be wise to buy the stock now despite the potential decline in revenue.
For the fourth quarter, GILD’s EPS is expected to increase 5.5% year-over-year to $1.76. However, its revenue for the same quarter is expected to decline 3.9% year-over-year to $7.10 billion.
